Mr. Clark, I'm sorry. I'm going to interrupt you.
How did you reach that $12-million cap?
There are a lot of drugs out there. I'm going to give you an example of cystic fibrosis. I know a lot of members are getting emails and phone calls, and I have a lot of constituents with cystic fibrosis.
Orkambi was refused in Canada by CADTH. I'm wondering if you have made any analysis on a drug like Trikafta or any of the other drugs for cystic fibrosis. Did they exceed $12 million for revenue in Canada? Patient access should be an important part here.